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Glaucoma is the second leading cause of blindness worldwide. Physicians often use surrogate
endpoints to monitor the progression of glaucomatous neurodegeneration. These approaches are
limited in their ability to quantify disease severity and progression due to inherent subjectivity,
unreliability, and limitations of normative databases. Therefore, there is a critical need to identify
specific molecular markers that predict or measure glaucomatous neurodegeneration. Here, we
demonstrate that growth differentiation factor 15 (GDF15) is associated with retinal ganglion cell
death. Gdf15 expression in the retina is specifically increased after acute injury to retinal ganglion
cell axons and in a murine chronic glaucoma model. We also demonstrate that the ganglion cell
layer may be one of the sources of secreted GDF15 and that GDF15 diffuses to and can be detected
in aqueous humor (AH). In validating these findings in human patients with glaucoma, we find not
only that GDF15 is increased in AH of patients with primary open angle glaucoma (POAG), but also
that elevated GDF15 levels are significantly associated with worse functional outcomes in glaucoma
patients, as measured by visual field testing. Thus, GDF15 maybe a reliable metric of glaucomatous
neurodegeneration, although further prospective validation studies will be necessary to determine
if GDF15 can be used in clinical practice.
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Glaucoma is the second leading cause of blindness around the world (1). It is a group of heterogeneous
diseases characterized by neuroretinal degeneration associated with death of retinal ganglion cells (RGCs),
which in turn leads to optic neuropathy. In glaucoma, progressive optic neuropathy, if left untreated, leads
to visual field (VF) defects that may ultimately result in irreversible blindness.
Numerous factors — including genetics and race, as well as ocular characteristics such as intraocular
pressure (IOP) and central corneal thickness — have been identified as risk factors in the development and
progression of glaucoma (2). Currently, all medical and surgical therapies for glaucoma focus on lowering
IOP as a strategy to protect RGCs from cell death. Although neuroprotection for glaucoma would be highly desirable, therapeutic strategies that have focused on neuroprotection have thus far failed to demonstrate
efficacy in clinical trials, with no agents currently approved by regulatory authorities (3).
Another impediment for effective glaucoma treatment is the paucity of molecular markers that predict
progression of glaucomatous neurodegeneration that results in optic neuropathy (4). Treating physicians
have generally relied on VF testing, IOP measurement, and optic nerve monitoring as metrics for assessing
whether disease is adequately controlled (5). However, the nature of VF testing, lack of precise correlation
of IOP with disease risk, and lack of validated normative databases for optic nerve imaging techniques,
such as optical coherent tomography (OCT), contribute to the persistent challenges of glaucoma management. Of significant concern, these evaluations presently form the basis for treatment decisions regarding
additional medical and surgical interventions to prevent disease progression and vision loss (6). Therefore,
there is an acute need to identify specific molecular markers that quantify glaucomatous neurodegeneration
by accurately and objectively measuring RGC-specific cell death.
In this study, we have, to our knowledge, characterized in mice and rats a novel molecular marker of
glaucomatous neurodegeneration. We have further validated our findings in human glaucoma patients
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with varying degrees of disease severity. These results highlight a protein with potential use as a marker of
glaucomatous neurodegeneration.

Results
Gdf15 expression is selectively increased in the retina following RGC axonal injury. Our goal was to identify specific
markers of RGC death that could potentially be used to accurately and reliably predict or measure glaucomatous neurodegeneration. Given the strong association between neuroinflammation and glaucomatous
optic neuropathy (7), we performed a retinal cytokine/growth factor–focused PCR array consisting of 88
genes (ILs, TNF and TGF superfamilies, growth factors, interferons, chemokines, and others) to identify
factors whose expression correlates specifically with RGC death. In order to identify factors unique to
RGC death, we used 3 different murine models of disease: optic nerve crush (ONC) as a model of axonal
injury and RGC-specific death as seen in glaucoma, light-induced retinal degeneration (RD) as a model of
photoreceptor-specific cell death, and endotoxin-induced uveitis (EIU) as a model of ocular inflammation
(8–10). By comparing the retinal gene expression profiles associated with these 3 murine models of disease
and focusing specifically on factors that are uniquely identified in the ONC model but not the RD and EIU
models, we could identify the factors that were uniquely associated with RGC death.
The results from the retinal cytokine/growth factor–focused array revealed that growth differentiation
factor-15 (Gdf15), a member of the transforming growth factor-β (TGF-β) superfamily, was the only gene
that was significantly altered in retinas 24 hours after ONC but not after RD and EIU (Figure 1, A–C,
Table 1, and Supplemental Table 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.91455DS1). We also examined Gdf15 gene expression in the retina at time points
later than 24 hours in all 3 disease models. The results showed that there was no significant increase of
Gdf15 in the retina of both EIU and RD models (Supplemental Figure 1, B and C), while Gdf15 expression
in ONC model retina was significantly increased even at 72 hours (Supplemental Figure 1A).
We also examined Tgfb2 gene expression in the retina because of its previously described association
with human primary open angle glaucoma (POAG) (11–13) and because GDF15 is a member of the TGF-β
superfamily (14). In terms of rodent models of glaucoma, no rodent glaucoma model has convincingly
demonstrated elevated Tgfb2 gene expression in the retina. However, given the reported associations with
human POAG, it was important to examine the specificity of Gdf15 by using Tgfb2 as a control. The result
showed that the expression of Tgfb2 in the retina was unchanged in all 3 disease models 24 hours after each
treatment (Figure 1D). Of interest, expression of other growth differentiation factor family members were
unchanged in the retina 24 hours after ONC (Figure 1E).
To determine whether these changes in Gdf15 gene expression after ONC led to differences in protein
secretion, we analyzed GDF15 protein level in aqueous humor (AH) of eyes after ONC. ELISA measurements showed that GDF15 levels in AH were significantly increased 24 hours after ONC (Figure 1F).
These results suggest that GDF15 may be a specific molecular marker of RGC death following axonal
injury to the optic nerve.
GDF15 protein level in AH is not affected by aging. The incidence of glaucoma increases exponentially
with aging (15). Therefore, an effective molecular marker of glaucomatous neurodegeneration must
be able to discriminate between physiologic aging and the transition to age-associated eye diseases
such as glaucoma. To determine whether Gdf15 expression changes with age, we examined the retina
and AH of young (6-week-old) and old (18-month-old) mice for Gdf15 gene expression and GDF15
protein levels, respectively. We found no difference between young and old mice in the expression of
Gdf15 (Figure 2A) and Tgfb2 (Figure 2B) in the retina. In addition, GDF15 protein levels in AH were
also unaffected by aging (Figure 2C). These results suggest that GDF15 may be able to discriminate
between aging and glaucomatous neurodegeneration and may, therefore, be useful as a molecular
marker of glaucomatous neurodegeneration.
Gdf15 expression was increased only in the ganglion cell layer (GCL) following axonal injury to the optic nerve.
To localize Gdf15 expression in the eye, we performed in situ hybridization. The results showed that Gdf15
was minimally expressed at baseline in the retina (Figure 3A), cornea (Supplemental Figure 2A), lens (Supplemental Figure 2B), and ciliary processes (Supplemental Figure 2C). In the retina, Gdf15 expression was
present in the GCL, the inner nuclear layer (INL), and the outer nuclear layer (ONL) (Figure 3A).
Given these numerous potential sources of secreted GDF15, we sought to determine the cellular source
of increased GDF15 in AH following axonal injury to the optic nerve. In order to do so, we analyzed
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Figure 1. Gdf15 expression is selectively increased in the retina following retinal ganglion cell (RGC) axonal injury. (A) Venn diagram of upregulated
genes in retinal cytokine/growth factor–focused PCR array (n = 3 for optic nerve crush [ONC] and its control, n = 4 for endotoxin-induced uveitis [EIU] and
its control, n = 4 for light-induced retinal degeneration [RD] and its control). (B) Venn diagram of downregulated genes in retinal cytokine/growth factor–
focused PCR array. (C) Retinal gene expression of Gdf15 from PCR array in ONC, EIU, and RD models 24 hours after each intervention. (D) Retinal gene
expression of Tgfb2 from PCR array in ONC, EIU, and RD models 24 hours after each intervention. (E) Retinal gene expressions of growth differentiation
factor family members 24 hours after ONC (n = 4–5 per group). (F) GDF15 protein level in aqueous humor (AH) 24 hours after ONC (n = 3 per group). Values
are mean ± SD. **P < 0.01 and ***P < 0.001 by 2-tailed unpaired t test.

different tissue compartments within the ONC eyes. We analyzed the anterior segment (AS) of the eye
(including cornea, trabecular meshwork, iris, ciliary body, and ciliary processes), lens, and retina. Increased
Gdf15 expression was observed only in the retina 24 hours after ONC (Figure 3, B and C), with no change
in Gdf15 expression in the AS and lens (Figure 3, B and C, and Supplemental Figure 3, A–C).
To determine which cells within the retina were the sources of increased Gdf15 expression, we performed in situ hybridization of Gdf15 in the retina 24 hours after ONC. The results showed that expression
of Gdf15 was increased in GCL, but not in INL and ONL (Figure 3, D–G). To obtain more accurate
quantification of Gdf15 expression in specific retinal layers, we performed laser microdissection (LMD),
separating the retina into GCL, INL, and ONL. As predicted, only the GCL — but not the INL and ONL
— showed increased Gdf15 expression 24 hours after ONC (Figure 3H). These results indicate that GCL
may be one of the sources of the increased GDF15 secretion after axonal injury to the optic nerve.
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Table 1. Upregulated genes in retinal cytokine/growth factor–focused PCR array
ONC

Group 1
(upregulated in only ONC)
Gdf15
Group 2
(upregulated in only EIU)
Ccl19
Mstn(Gdf8)
Tnfsf10
Ctf1
Group 3
(upregulated in only RD)
Il7
Il12b
Csf3(GCSF)
Lefty1
Lif
Osm
Bmp1
Lta
Ltb
Tnfsf18
Spp1
Group 4
(upregulated in ONC and EIU)
Tgfb1
Group 5
(upregulated in EIU and RD)
Il6
Il10
Csf1(MCSF)
Bmp2
Group 6
(upregulated in all)
Ccl2
Il1a
Il1b
Pgf (Plgf)
Tnf
Scgb3a1

EIU

RD

P value

fold-change

P value

fold-change

P value

fold-change

0.000

2.999

0.244

0.775

0.304

0.856

0.366
0.994
0.987
0.288

1.343
0.997
0.994
0.995

0.004
0.025
0.029
0.026

7.555
1.599
2.648
1.745

0.339
0.992
0.986
0.063

0.869
1.002
0.995
0.494

0.327
0.502
0.268
0.388
0.257
0.147
0.403
0.208
0.258
0.627
0.392

1.399
0.779
1.573
1.323
1.595
2.019
1.189
2.344
1.588
0.861
1.324

0.555
0.563
0.108
0.548
0.062
0.378
0.425
0.511
0.248
N/A
0.057

1.188
1.220
5.681
1.416
1.986
1.295
1.123
1.358
1.984
N/A
0.990

0.002
0.021
0.029
0.022
0.039
0.042
0.000
0.011
0.048
0.042
0.027

3.909
10.101
5.189
1.971
18.106
3.986
1.993
3.399
3.146
4.105
2.483

0.000

2.002

0.033

2.378

0.351

0.792

0.374
N/A
0.260
0.512

1.314
N/A
1.592
0.796

0.009
0.001
0.033
0.024

3.482
6.754
1.771
1.746

0.048
0.000
0.000
0.026

3.301
9.350
2.257
0.622

0.044
0.026
0.013
0.000
0.000
0.000

9.411
3.330
6.677
2.014
1.989
1.993

0.001
0.032
0.005
0.000
0.000
0.002

15.864
2.399
8.022
2.655
3.153
76.716

0.015
0.020
0.042
0.022
0.001
0.000

28.431
3.993
2.850
1.980
15.863
128.791

ONC, optic nerve crush model; RD, outer retinal photoreceptor degeneration model; and EIU, ocular inflammation model.

Although we found that GCL may be the source of the increased GDF15 in AH after axonal injury to
the optic nerve, it has previously been reported that Gdf15 is also upregulated in macrophages in response to
a variety of stimuli, including IL1B, TNFA, IL2, and TGFB (16). As some of these cytokines/growth factors were also found to be upregulated in eyes after ONC (Table 1), it remained possible that macrophages
infiltrating into the retina and localizing to the GCL were the source of the secreted GDF15. To quantify
the extent of macrophage infiltration into the retinas after ONC, we analyzed retinal F4/80 expression as a
measure of macrophage infiltration. Quantitative PCR (qPCR) analysis, as well as IHC, demonstrated that
there was no significant change in F4/80 expression or macrophage infiltration into the retina after ONC
compared with controls (Figure 3, I and J, and Supplemental Figure 4). These results validated that macrophages were not the major sources of secreted GDF15 in AH following axonal injury to the optic nerve.
To confirm the generalizability of these results, we also measured GDF15 level in rat AH after ONC.
Similar to the results obtained in mice, we found a significant increase in the expression of Gdf15 after
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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ONC (Figure 4A) in the retina, while
Tgfb2 expression in the retina remained
unchanged (Figure 4B). In addition, ELISA confirmed a significant increase in
GDF15 protein levels in AH after ONC
(Figure 4C).
GDF15 level in AH is elevated in a murine
chronic glaucoma model. ONC causes acute
axonal injury of RGCs, while axonal injury of RGCs in a majority of human glaucoma is chronic. As such, we were interested
in validating our findings in an established
model of chronic glaucoma.
Figure 2. GDF15 in aqueous humor (AH) is not affected by aging. (A) Retinal gene expression of Gdf15
We chose DBA/2J mouse strain as
in young (6 weeks old) and old (18 months old) mice (n = 4 per group). (B) Retinal gene expression of
a
model
of chronic glaucoma. DBA/2J
Tgfb2 in young and old mice (n = 4 per group). (C) GDF15 protein level in AH in young and old mice (n = 5
per group). Values are mean ± SD.
mouse strain is considered to be a model of
chronic, pigmentary glaucoma that is characterized by pigment liberation throughout
the AS (17–19). Iris pigment dispersion and subsequent iris stromal atrophy in DBA/2J mice are caused
by mutations in the Gpnmb and Tyrp1 genes, respectively (18, 20). Pigment dispersion becomes evident at
5–6 months, and IOP elevation can be detected in most DBA/2J mice by the age of 9 months (17). These
changes were followed by the death of RGCs, optic nerve atrophy, and optic nerve cupping (17). Thus,
DBA/2J mouse strain is widely used to evaluate mechanisms of pressure-related chronic ganglion cell
death and optic nerve atrophy. We used 1-year-old DBA/2J mice as a model for chronic glaucoma and
compared them to 3-month-old DBA/2J mice with normal IOP as controls.
As predicted, IOP was significantly elevated in the glaucoma group (1-year-old DBA/2J mice) compared with control group (3-month-old DBA/2J mice) (Figure 5A). We also confirmed a significant
decrease of RGC counts in the glaucoma group (Supplemental Figure 5, A and B). As seen in the ONC
model, we found a significant increase in the expression of Gdf15 (Figure 5B) in the retina of mice with
glaucoma compared with control mice, while there was no difference in retinal Tgfb2 expression (Figure
5C). In addition, ELISA confirmed a significant increase in GDF15 protein levels in AH of mice with
glaucoma when compared with control mice (Figure 5D).
These findings suggest that the increase in GDF15 protein level in AH after axonal injury to the optic
nerve is potentially generalizable to mouse glaucoma and further strengthens the possibility that it may
represent a valuable molecular marker of glaucomatous neurodegeneration.
GDF15 levels in AH of POAG patients are significantly associated with mean deviation measured by VF testing. To determine how well GDF15 can quantify the glaucomatous neurodegeneration, we analyzed
the GDF15 protein levels in AH of patients with POAG and controls without glaucoma. As described
in the Methods, POAG patients were classified into 3 groups with increasing severity of disease using
Hodapp-Parrish-Anderson (HPA) criteria (21). Demographic data for POAG patients and controls without
glaucoma are shown in Table 2. There were no significant differences in age (Table 2, Supplemental Figure
6), sex, diabetic status, and race (Table 2) between the different groups (control and POAG stage 1, stage 2,
and stage 3). AH was collected prior to surgical intervention as described in the Methods. Consistent with
the results of animal experiments, POAG patients had significantly higher levels of GDF15 (median, 63.4
pg/ml; mean, 131.3 pg/ml) in their AH compared with controls (median, 2.0 pg/ml; mean, 2.7 pg/ml)
(Figure 6A). In addition, GDF15 levels were not only higher in AH of POAG patients, but also demonstrated trends of increased levels with increasing severity of disease (Figure 6, B–E). Importantly, among
all POAG patients, GDF15 levels did not differ by sex (Figure 6F), diabetic status (Figure 6G), and race
(Figure 6H) and were not correlated with age (Figure 6I) and average IOP (Figure 6J). Furthermore, there
were no significant differences in topical glaucoma medications prescribed for POAG patients in various
categories (Supplemental Figure 7A) or the type of surgery performed for POAG patients at the time of
sample collection (Supplemental Figure 7B).
Since TGFB2 has been reported to be increased in AH of POAG patients, we also measured
TGFB2 protein level in AH of the same POAG patients and controls. As predicted, TGFB2 levels
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Figure 3. Ganglion cell layer (GCL) showed increased Gdf15 expression following axonal injury to the optic nerve. (A) In situ hybridization of Gdf15 in the
mid peripheral retina (n = 3 per group, representative pictures are shown). ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale
bar: 50 μm. (B and C) Gene expression of Gdf15 in anterior segment (AS), lens, and retina (B) 6 hours (n = 3 per group) and (C) 24 hours after optic nerve
crush (ONC) (n = 6 per group). (D) In situ hybridization of Gdf15 in the mid-peripheral retina 24 hours after ONC (n = 4 per group, representative pictures are
shown). Scale bar: 50 μm. (E–G) High-magnification images from D. Scale bar: 50 μm. (E) In situ hybridization of Gdf15 24 hours after ONC in GCL. (F) In
situ hybridization of Gdf15 24 hours after ONC in INL. (G) In situ hybridization of Gdf15 24 hours after ONC in ONL. (H) Gdf15 gene expression in GCL, INL,
and ONL of the retina following the isolation by laser microdissection 24 hours after ONC (n = 4 per group). (I and J) F4/80 gene expression in the retina (I)
6 hours (n = 3 per group) and (J) 24 hours after ONC (n = 5 per group). Values are mean ± SD. ***P < 0.001 by 2-tailed unpaired t test.

were increased in AH of POAG patients compared with controls (Figure 7A). However, in contrast to
GDF15, there were no significant differences in TGFB2 among different disease severity groups (Figure
7B). Among all POAG patients, although TGFB2 levels showed a significant difference by sex (Supplemental Figure 8A), they did not differ by diabetic status (Supplemental Figure 8B) and race (Supplemental Figure 8C), and they were not correlated with age (Supplemental Figure 8D) and average IOP
(Supplemental Figure 8E).
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Furthermore, to investigate if GDF15
and TGFB2 levels in AH were progressively
increased with increasing severity of disease or
not, we generated a multivariable linear regression model (Figure 8). This model was adjusted
for diabetic status (dichotomized as yes or no),
IOP (averaged over last 3 visits), age (continuous
variable), and race (dichotomized as European
descent or African American). After controlling
for these covariates, log-transformed GDF15
level was a significant predictor of worse mean
deviation (β-coefficient = –2.0, 95% CI: –3.7 to
Figure 4. Elevated GDF15 level in aqueous humor (AH) of rats following optic nerve crush (ONC).
(A) Gdf15 expression in the retina of rats 24 hours after ONC (n = 5 per group). (B) Tgfb2 expression
–0.2; t = –2.3, P = 0.027), suggesting that a one
in the retina of rats 24 hours after ONC (n = 5 per group). (C) GDF15 protein level in AH of rats 24
log-unit increase in GDF15 levels is associated
hours after ONC (n = 5 per group). Values are mean ± SD. ***P < 0.001 by 2-tailed unpaired t test.
with a ~2.0 decrease in mean deviation. Notably, log-transformed TGFB2 levels were not a
significant predictor of mean deviation (β-coefficient = –0.3, 95% CI: –8.0 to –7.5, t = –0.1, P = 0.945). The final model had an R2 = 0.384, indicating
good explanatory power. Overall, these results suggest that elevated GDF15 levels are significantly
associated with worse functional outcomes in glaucoma patients, as measured by VF testing.

Discussion
In this study, we were interested in identifying a specific molecular marker that accurately predicted progression of glaucomatous neurodegeneration. We hypothesized that a protein secreted by the retina may
specifically correlate with RGC death and may, thus, be a useful molecular marker that predicts progression
of glaucomatous neurodegeneration. Based on this hypothesis, we performed retinal cytokine/growth factor–focused PCR array to identify factors that were associated specifically with RGC death. Our array results
showed that GDF15 may be a novel and unique molecular marker of RGC death in glaucoma, as it was not
elevated in models of ocular inflammation (EIU) or outer retinal photoreceptor degeneration (RD).
GDF15 is a member of TGF-β superfamily (16). GDF15 is expressed in both the CNS and the peripheral nervous system (PNS) (22). Although the precise biological function of GDF15 in the nervous system,
including the retina, remain poorly understood, previous literature demonstrated its neurotrophic or neuroprotective effect in CNS (22) and PNS (23, 24). In addition, GDF15 has previously been demonstrated to

Figure 5. Elevated GDF15 level in aqueous humor (AH) of chronic glaucoma mouse model. (A) Intraocular pressure (IOP) of control (3-month-old DBA/2J
mice) and glaucoma (1-year-old DBA/2J mice) (n = 14 per group). (B) Gdf15 expression in the retina of control and glaucoma mice (n = 10 per group). (C)
Tgfb2 expression in the retina of control and glaucoma mice (n = 10 per group). (D) GDF15 protein level in AH of control and glaucoma mice (n = 12 per
group). Values are mean ± SD. **P < 0.01 and ***P < 0.001 by 2-tailed unpaired t test.
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Table 2. Characterization of primary open angle glaucoma (POAG) patients (stage 1 to stage 3) and controls
AgeA
SexB
Diabetic statusB
RaceB

Mean ± SD
Range
male
female
no DM
DM
ED
AA

All patients

Control

POAG Stage 1

POAG Stage 2

POAG Stage 3

66.9 ± 14.9
47-90
27
53
57
23
57
23

65.8 ± 11.7
47-88
9
14
16
7
15
8

70.4 ± 8.8
52-88
5
18
17
6
16
7

70.5 ± 8.5
56-82
6
9
13
2
14
1

70.1 ± 12.0
52-90
7
12
11
8
12
7

A

B

There were no significant differences between different groups (controls, POAG stage 1, stage 2, and stage 3) by one-way ANOVA test. There were no
significant differences between different groups by chi-square test. DM, diabetes mellitus; AA, African American; ED, European descent.

be upregulated in the retina after axonal injury to the optic nerve (25). However, the magnitude and time
course of RGC death after axonal injury was not different in mice that are genetically deficient in GDF15
compared with littermate controls, which suggests that it did not influence the temporal progression of
RGC death (25). Of interest, it has also been reported that GDF15 provides independent prognostic information on cardiovascular events beyond previously identified cardiovascular risk factors and other markers
of chronic and acute coronary disease (26, 27).
In addition to the increase of Gdf15 expression in the retina after axonal injury to the optic nerve, we
detected increased Gdf15 expression only in GCL of the retina, although other parts of the eye do indeed
express low levels of Gdf15 at baseline. In both mouse and rat models, GDF15 levels in AH increased after
acute axonal injury to the optic nerve. The source of this secreted GDF15 may be the GCL, since GCL
was the only cell population in the eye to exhibit increased gene expression after ONC. We also showed
increased Gdf15 expression in the retina and increased GDF15 levels in AH of DBA/2J mice, a well-characterized murine chronic glaucoma model (17–19). Based on these results, we concluded that GDF15
secreted in to the AH by GCL may be a quantifiable measure of glaucomatous neurodegeneration.
We did not find an increase in retinal Tgfb2 gene expression in the ONC model or the murine chronic
glaucoma model. As described in the results section, many studies have reported an association between
TGFB2 in AH and POAG in humans. However, the main source of TGFB2 in AH is either the epithelial
layer of the ciliary body (28) or the lens (29). Previous studies have shown that TGFB2 affected the trabecular meshwork, which is an important tissue for draining AH and maintaining normal IOP (30). As complex
changes in the trabecular meshwork gradually affect its ability to drain AH from the anterior chamber, it
can lead to elevated IOP. As such, increased TGFB2 in AH of POAG patients is not caused by the stress or
damage of retinal cells induced by high IOP, and although animal models replicate some features of human
POAG, they do not reproduce each facet of human glaucoma. This may be a reason TGFB2 protein levels
are high in AH of POAG patients but not in the retinas after ONC or in the murine chronic glaucoma model.
We validated these findings in a well-characterized cohort of human patients either without glaucoma
or with POAG. We classified POAG patients to 3 different severity groups (stage 1, 2, and 3) according to
HPA criteria. As described above, we sought to identify specific markers that accurately predict progression of glaucomatous neurodegeneration. However, due to the limitation of the study design (retrospective
cross-sectional study), we could not have appropriate dependent variables for glaucoma progression. Therefore, we had to use glaucoma severity as a surrogate-dependent variable for glaucoma progression in this
study. Our multivariable linear regression model proved that GDF15 levels in AH of POAG patients, but
not TGFB2, are significantly associated with glaucoma severity. These findings render GDF15 an attractive
molecular marker of glaucomatous neurodegeneration, although further prospective study is needed in the
future because glaucoma severity is no more than a surrogate-dependent variable for glaucoma progression;
thus, we could not prove a direct relationship between GDF15 and glaucoma progression in this study.
We acknowledge that there are several limitations in this study. First, animal models we used in
this study do not exactly reflect usual biological process of human glaucoma. The ONC model is an
acute axonal injury model, whereas the majority of human glaucoma have chronic features. Although
DBA/2J mouse strain is a model of chronic glaucoma, it is considered as pigmentary glaucoma model,
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Figure 6. Elevated GDF15 level in aqueous humor (AH) of primary open angle glaucoma (POAG) patients. (A) GDF15 protein level in AH of control patients (n
= 23) and POAG patients (n = 57). ***P < 0.001 by Mann Whitney U test. (B) GDF15 protein level in control patients (n = 23) and POAG stage 1 (n = 23), stage 2
(n = 15), and stage 3 (n = 19) patients. P < 0.001 by Kruskal-Wallis test. *P < 0.05 and ***P < 0.001 by Dunn’s multiple comparison. Arrows in the graph indicate
an individual case for each stage of POAG with the highest GDF15 level in AH for which the visual fields are illustrated. (C–E) Representative visual field images
of POAG patient for (C) stage 1: 76 y/o, male, OD, MD: –1.63, GDF15: 126.8 pg/ml; (D) stage 2: 67 y/o, male, OD, MD: –10.82, GDF15: 466.1 pg/ml; and (E) stage 3:
88 y/o, female, OS, MD: –18.01, GDF15: 703.1 pg/ml. OD, oculus dexter (right eye); OS, oculus sinister (left eye); MD, mean deviation. (F–H) GDF15 protein level
in AH of POAG patients did no differ by (F) sex: male (n = 18) vs. female (n = 39), (G) diabetes status: patients without DM (no DM: n = 41) vs. with DM (DM: n
= 16), or (H) race: European descent (ED: n = 42) vs. African American (AA: n = 15). (I) Correlation between age and GDF15 protein level in AH of POAG patients
(n = 57, Pearson Correlation Coefficient = 0.052, 95% CI: –3.08 to 4.82, P = 0.662). (J) Correlation between average IOP and GDF15 protein level in AH of POAG
patients (n = 57, Pearson Correlation Coefficient = –0.037, 95% CI: –8.72 to 6.60, P = 0.78). Values are median with interquartile range.
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Figure 7. TGFB2 level in aqueous humor (AH) of primary open angle glaucoma (POAG) patients. (A) TGFB2 protein level in AH of control patients (n = 23)
and POAG patients (n = 57). *P < 0.05 by Mann Whitney U test. (B) TGFB2 protein level in control patients (n = 23) and POAG stage 1 (n = 23), stage 2 (n =
15), and stage 3 (n = 19) patients. P < 0.05 by Kruskal-Wallis test. *P < 0.05 by Dunn’s multiple comparison. Values are median with interquartile range.

in which DCs are known to phagocytose pigment granules in the AS of DBA/2J mice (19). Thus, when
we analyze the AH of DBA/2J mice, we have to consider confounding features, including the effect of
phagocytic DCs in the AS and inflammation in this model of glaucoma. Second, our human study might
have selection bias. This study included stage 1 to stage 3 POAG patients classified by HPA criteria as
described in the Methods section, but not stage 4 and stage 5 POAG patients that have severe or end-stage
VF defect, since there was no surgical case in these categories during the study period. With this limitation of study design, it could be possible that GDF15 levels are low in stable but severe glaucoma patients
that are not signed up for surgeries; this leads to different conclusion about the correlation between
GDF15 and glaucoma severity. Third, although our multivariable linear regression model statistically
proved that GDF15 levels in AH of POAG patients are significantly associated with glaucoma severity,
GDF15 failed to detect glaucoma in some cases at all stages of the disease. As discussed above, due to
the limitation of the study design, we had to use glaucoma severity as a surrogate-dependent variable
for glaucoma progression in this study. However, based on our results of animal experiments, GDF15 in
AH has strong potential to be associated with RGC death in the retina or glaucoma progression. Thus,
future prospective validation studies will be necessary to determine if GDF15 in AH is associated with
glaucoma progression and whether the measurement of GDF15 in AH can be used in clinical practice.
In conclusion, our data suggest that measurement of
GDF15 in AH might give us quantitative information about
glaucomatous neurodegeneration. In addition to conventional IOP measurements, VF test, and disc appearance,
this information may enhance current treatment algorithms
for glaucoma. Further prospective validation studies will be
necessary to determine if GDF15 in AH is correlated with
glaucoma progression and can be used in clinical practice.

Methods
Figure 8. GDF15 level in aqueous humor (AH) of primary open angle glaucoma
(POAG) patients, but not TGFB2, is a significant predictor of worse mean deviation measured by visual field (VF) testing. The results of multivariable linear
regression model showed log-transformed GDF15 levels (β = –2.0, 95% CI: –3.7 to
–0.2, t = –2.3, P = 0.027) but not log-transformed TGFB2 levels (β = –0.3, 95% CI:
–8.0 to 7.5, t = –0.1, P = 0.945) predict worse mean deviations on VF testing after
controlling for age, race, intraocular pressure (IOP), and diabetic status.
insight.jci.org   https://doi.org/10.1172/jci.insight.91455

Animals. All mice (The Jackson Laboratory) and rats
(Charles Rivers Laboratories) were housed in a temperature-controlled room under a 12-hour light/dark cycle, with
free access to food and water. Six-week-old C57BL/6J mice
were used for ONC and EIU experiments. Six-week-old
129S1/SvImJ mice were used for RD experiment. Six-weekold and 18-month-old C57BL/6J mice were used for young
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and old mice comparison. Three-month-old and 1-year-old DBA/2J mice were used as a chronic glaucoma
model and its control. Eight-week-old Sprague Dawley rats were used for rat ONC experiment.
ONC model for mice. We performed ONC in mice as previously described to examine the effect of axonal
injury on RGC survival (8). Briefly, we anesthetized 6-week-old C57BL/6J mice with an i.p. injection of
anesthetic cocktail (86.9 mg/kg ketamine and 13.4 mg/kg xylazine diluted in PBS). After ensuring adequate anesthesia, we incised the nasal/ventral conjunctiva and pulled away connective tissue using forceps.
Then, we pinched and held the optic nerve for 10 seconds using the Dumont #N7 self-closing curved
forceps (Fine Science Tools) 1–2 mm behind the bulbus. The left eye of each mouse served as the sham surgery control: conjunctiva of the left eye was incised without an ONC. After euthanasia by CO2 inhalation
at various time points following ONC, we collected eye tissues (retinas, ASs, and lens) for further analyses.
Eyes that demonstrated significant hemorrhage during the procedure were excluded from further analysis.
ONC model for rats. We performed ONC in rats to induce axonal injury to RGC as previously described (31). Briefly, 8-week-old Sprague Dawley rats were anesthetized with isoflurane (Henry
Schein) in oxygen (5% for induction and 2% for maintenance respectively, 2 l/min). The conjunctiva
was dissected away from the orbit using spring scissors. The left optic nerve was then exposed and
crushed for 10 seconds using Dumont #5 forceps (Fine Science Tools). The conjunctiva of the right
eye served as the sham surgery control and was incised; the optic nerve was exposed, but no injury was
performed. Rats were sacrificed at various time points after the crush by CO2 inhalation, and the retinas
were harvested for downstream analyses. The eyes with intravitreal inflammation or severe hemorrhage
were excluded from the study.
Light-induced RD model. Light exposure to induce RD was performed as previously described (9). Briefly,
6-week-old 129S1/SvImJ mice were dark adapted overnight. Pupils were dilated with 2.5% phenylephrine
hydrochloride (Akorn), and the mice were exposed to 13,000 lux of white light for 1 hour. The mice were
then returned to normal light/dark cycle and sacrificed by CO2 inhalation at various time points after light
exposure in order to harvest the retinas for analyses. We used 129S1/SvImJ mice for the RD model because
C57BL/6J mouse strain is resistant against light-induced RD due to the gene mutation of RPE65 gene (32).
EIU model. The EIU model was performed as described previously (10). Briefly, 6-week-old
C57BL/6J mice received a single i.p. injection of 6.0 mg/kg body weight lipopolysaccharide from E.
coli (Sigma-Aldrich) diluted in PBS. Control mice were injected with PBS alone. Mice were sacrificed by
CO2 inhalation at various time points after EIU induction, and the retinas were harvested for analyses.
RNA isolation and real-time PCR. Total RNA was extracted from eye tissues with TRIzol reagent
(Thermo Fisher Scientific) following manufacturer’s instructions. For the samples collected by LMD,
total RNA was extracted using RNeasy Micro Plus kit (Qiagen) according to the manufacturer’s instructions. To synthesize cDNA, total RNA was added to the High Capacity cDNA Reverse Transcription
Kits (Thermo Fisher Scientific) and reverse-transcribed according to manufacturer’s instructions. qPCR
was performed with duplicate using the StepOnePlus Real Time PCR system (Thermo Fisher Scientific)
using TaqMan Real-Time PCR Assays (Thermo Fisher Scientific), and the mRNA was quantified using
the ΔΔCT method with Actb or Gapdh as the internal control. The primers used in this study are shown
in Supplemental Table 2.
PCR array. Cytokine/growth factor–focused PCR array was performed with duplicate using 96-well
Taqman Gene Expression Array plate (Thermo Fisher Scientific) according to manufacturer’s instructions
with Actb as the internal control. The primers used in this cytokine/growth factor–focused PCR array are
shown in Supplemental Table 3.
LMD. Laser-capture microdissection was performed as described previously (33). Briefly, eyeballs were
embedded in OCT compound (Sakura Finetek) and immediately flash frozen on dry ice. Cryo blocks were
cut into 10-μm sections and placed on membrane slides (Leica). The slides were kept on dry ice and then
fixed with 100% ethanol following Hematoxylin staining. LMD was performed using Leica LMD6000
LMD system (Leica). The GCL, INL, and ONL were separately collected.
In situ hybridization. To detect Gdf15 mRNA expression in the eye, we performed in situ hybridization
using the RNAscope 2.5 HD Detection Kit (Advanced Cell Diagnostics) according to the manufacturer’s
instructions. Briefly, eyes from 6-week-old C57BL/6J mice were fixed with 10% neutral buffered formalin
for 24 hours and then embedded in paraffin. The paraffin-embedded samples were then cut into 4-μm slices
on glass slides. In addition to the Gdf15 probe (catalog 318521), the Dapb probe (catalog 301143) was used
as a negative control. Hematoxylin was used as a counter stain.
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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IHC. Eyeballs were embedded in OCT compound (Sakura Finetek) and immediately flash frozen on
dry ice. Cryo blocks were cut into 10-μm sections and placed on superfrost plus microscope slides (Thermo
Fisher Scientific). Slides were postfixed for 15 minutes in 10% Neutral Buffered Formalin (catalog 305-510;
Protocol), washed in 4 changes of PBS and blocked in 10% BSA in PBS for 30 min at room temperature.
Anti–mouse F4/80 primary antibody (catalog 14-4801-82; Thermo Fisher Scientific) was applied overnight
using a dilution of 1:200 in blocking solution. Following 3 washes of PBS for 3 minutes each, Alexa 546–
conjugated goat anti-rat secondary antibody (Thermo Fisher Scientific) was applied to the slides at 1:500
for 1 hour at room temperature. Slides were washed with PBS 3 times for 3 minutes each and mounted
using SlowFade Gold with Dapi (Thermo Fisher Scientific). All incubations were performed in a humidified chamber. Images were obtained on a fluorescence microscope (Olympus BX51).
ELISA. GDF15 in mouse and rat AH was measured using Quantikine Mouse/Rat GDF15 ELISA
Kit (R&D Systems) according to the manufacturer’s instructions. GDF15 in human AH was measured by
using human GDF15 Quantikine ELISA Kit (R&D Systems) according to the manufacturer’s instructions.
Human GDF15 levels below the limit of detection of 4 pg/ml were replaced by a nonzero value (i.e., 1, 2,
or 3 pg/ml), using a random integer generator (www.random.org). To measure TGFB2 in human AH, we
used Quantikine ELISA Human TGFB2 (R&D Systems) according to manufacturer’s instructions. Briefly,
1/5 volume of 1 N HCl was added to the samples and incubated 10 minutes at room temperature. After the
incubation, 1/5 volume of 1.2 N NaOH/HEPES was added, and total TGFB2 was measured immediately.
Collection of the AH from mice and rats. AH was collected from enucleated eyes using syringe with a
34-gauge needle (Hamilton). A total of 2–3 μl of AH was collected from each mouse, and 2–3 samples were
pooled for ELISA. A total of 10–15 μl of AH was collected from each rat, and individual samples were
measured by ELISA.
IOP measurement of mice. To measure IOP of the mice, we used TONOLAB (Colonial Medical Supply)
following manufacturer’s instructions after anesthetizing the mice with an i.p. injection of anesthetic cocktail (86.9 mg/kg ketamine and 13.4 mg/kg xylazine diluted in PBS).
Immunostaining of RGCs. We used RNA-binding protein with multiple splicing (RBPMS) as a selective marker of mice RGCs (34). The eyes were enucleated, and the posterior segments were immediately
dissected and fixed with 4% paraformaldehyde in PBS for 1 hour. After being washed with PBS, the samples were blocked with 1% Triton and 5% BSA in PBS for 2 hours and then incubated with rabbit polyclonal antibody against RBPMS (1:200, catalog ab194213, Abcam) overnight at 4°C. Binding of primary
antibody was localized with Alexa Fluor 488 goat anti-rabbit secondary antibody (1:500, Thermo Fisher Scientific). Finally, retinas were removed and mounted with mounting medium (ProLong Diamond
Antifade Mountant, Invitrogen), and they were viewed with a fluorescence microscope (Olympus BX51).
RGC density was determined as previously described with slight modification (35). Briefly, 4 standard
areas (0.58 × 0.43 mm) of each whole-mounted retina at the point of 0.2 mm from the optic disc were
randomly chosen, the labeled cells were counted, and the average number of RGCs/mm2 was calculated
and used for the further analysis.
Inclusion and exclusion criteria for human AH analysis. AH was collected from the patients undergoing
cataract and/or glaucoma surgery from December 2007 to November 2015. We selected POAG patients
without history of past pars plana vitrectomy (PPV) and ischemic diabetic retinopathy (DR). Patients without glaucoma, past PPV, and ischemic DR undergoing cataract surgery were selected as controls. Patients
with Fuchs’ corneal dystrophy (2 cases), congenital cataract (1 case), retinal detachment (1 case), and high
myopia > 31 mm axial length (1 case) were excluded.
Collection of the AH from human patients. Prior to the planned surgical procedure, a peripheral corneal
paracentesis was performed with a 15-degree blade near the limbus for entry into the anterior chamber. Via
a 30-gauge blunt cannula introduced on a 1-ml tuberculin syringe, 50–100 μl of AH was withdrawn and
immediately placed into a receptacle of dry ice and then transferred to a liquid nitrogen tank for storage at
–70oC until further analysis.
Classification of glaucoma patients. HPA criteria were used to classify glaucoma patients (20). In this
study, all POAG patients were classified into stage 1 to stage 3 based on HPA criteria.
Statistics. All statistical tests except for Fisher’s exact test were performed using GraphPad prism 6.
Fisher’s exact test was performed by R-3.3.1. For the data that are normally distributed, values represent
mean ± SD. For the data that are not normally distributed, values represent median with interquartile
range. P < 0.05 was considered statistically significant.
insight.jci.org   https://doi.org/10.1172/jci.insight.91455
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Kolmogorov-Smirnov test was used to check if the data is normally distributed. For the data that are
normally distributed, 2-tailed unpaired t test was used to compare 2 groups, and one-way ANOVA followed by Tukey’s HSD test for post-hoc analysis was used to compare 3 groups or more. For the data that
are not normally distributed, Mann Whitney U test was used to compare 2 samples, and Kruskal-Wallis
test followed by Dunn’s multiple comparison test for post-hoc analysis were used to compare 3 and more
samples. Pearson correlation analysis was used to analyze the correlation between 2 groups. The χ2 test
was used to compare the proportion of sex, diabetic status, and race in each group. Fisher’s exact test
was used to compare the proportion of type of surgery for POAG patients. To determine the relationship
between GDF15 and TGFB2 levels in AH and the extent of neurodegeneration in glaucoma patients as
measured by mean deviation on VF testing (average of up to 2 last visits), we generated a multivariable
linear regression model. Our model included the following predictor variables: log10-transformed GDF15
levels, log10-transformed TGFB2 levels, diabetic status (dichotomized as yes or no based on treating
physician’s diagnosis), age (continuous variable), race (dichotomized as European descent or African
American), and IOP (averaged over last 3 visits). We performed model diagnostics on the final model as
appropriate. Finally, the final reported model omitted a single case with a standardized residual of –2.99
based on the results of the sensitivity analysis.
Study approval. All animal experiments were conducted in accordance with Washington University in St.
Louis School of Medicine Animal Care and Use guidelines after approval by the Animal Studies Committee.
The research protocol for human study was approved by the Washington University School of Medicine Human Research Protection Office and the IRB in compliance with HIPAA guidelines and the tenets
of the Declaration of Helsinki. Written Informed consent was obtained from the patients prior to inclusion
in the study.
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